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ABSTRACT
Objective: The aim of the present work was to formulate and evaluate fast dissolving film containing lornoxicam.
Materials and Methods: To prepare the film, hydroxypropyl methylcellulose E5 and polyvinyl alcohol (PVA) were used as film-forming polymers 
by solvent casting method. Glycerine was used as plasticizer, aspartame, and mannitol as sweetener. All prepared films were evaluated for its weight 
variation, disintegration time, thickness, drug content, pH, dissolution study, and folding endurance. The drug-excipients compatibility study was 
done using differential scanning calorimetry (DSC) and Fourier transform infrared (FTIR).
Results: Satisfactory results obtained when PVA was used as film-forming polymer, and the drug was dispersed in the polymer solution using 
poloxamer 407 as a solubilizing agent. Formulation F2 is considered as the optimized formulation as it showed good folding endurance (>300), faster 
disintegration rate (30 s), and maximum in vitro drug release (87%) within 5 min. DSC and FTIR studies showed no interaction between drug and 
the polymers.
Conclusion: It can be concluded from the study that the fast dissolving film can be prepared for poorly water-soluble drug lornoxicam using PVA as 
a suitable film-forming polymer.
Keywords: Lornoxicam, Fast dissolving film, Hydroxypropyl methylcellulose E5, Polyvinyl alcohol, Solvent casting method.
INTRODUCTION
Despite so much of advancements in various delivery systems 
developed for the administration of various drugs through different 
routes such as oral, parenteral, transdermal, and nasal, the oral route 
is considered as the most convenient and the preferred route of 
administration [1]. The oral route of administration still continues 
to be widely used accepted route, contributing to 50–60% of total 
drug formulations due to ease of administration, self-medication, and 
pain avoidance as compared to parenteral [2]. Fast-dissolving drug 
delivery is rapidly gaining interest in the pharmaceutical industry. 
These systems either dissolve or disintegrate generally within a 
minute, without needing water or chewing [3]. Difficulty in swallowing 
(Dysphagia) is a common problem of all age groups, especially elderly 
and pediatrics, because of physiological changes associated with these 
groups of patients [4]. Fast dissolving films are very similar to ultra-
thin strip of a postage stamp in their shape, size, and thickness. Fast 
dissolving film is simply placed on the patient’s tongue or any oral 
mucosal tissue, instantly wet by saliva the film, and rapidly hydrates 
and adheres onto the site of application. It then rapidly disintegrates 
and dissolves to release the medication for oramucosal absorption 
or, with formula modifications, will maintain the quick-dissolving 
aspect but allow for gastrointestinal absorption to be achieved when 
swallowed [5].
Lornoxicam is a nonsteroidal anti-inflammatory drug (NSAID) of 
the oxicam class with analgesic (pain relieving), anti-inflammatory, 
and antipyretic (fever reducing) properties. It is available in oral 
and parenteral formulations. Lornoxicam inhibits the synthesis of 
prostaglandins through inhibition of cyclooxygenase enzyme [6]. 
Lornoxicam is classified as a low solubility and high permeability drug 
(Class II). Chemically, lornoxicam is (3E)-6-chloro- 3-[hydroxy(pyridin-
2-yl amino) methylene] -2-methyl-2, 3-dihydro- 4h- thieno [2, 3-e] [1,2] 
thiazin-4- one 1, 1-dioxide as shown in Fig. 1 [7].
The main objective of the study was to formulate and evaluate 
mouth-dissolving film containing lornoxicam using hydroxypropyl 
methylcellulose (HPMC E5) and polyvinyl alcohol (PVA) as film-forming 
polymers by solvent casting method.
MATERIALS AND METHODS
Materials
Lornoxicam and HPMC E5 were purchased from Wuhan Senwayer 
Century chemical Co., Ltd. PVA was obtained from Fine Indian chemicals. 
All other reagents and chemicals used were of analytical grade.
Methods
Determination of λmax
The standard solution of 100 μg/ml was scanned between 400 nm and 
200 nm in ultraviolet (UV) spectrophotometer against phosphate buffer 
solution pH 6.8 as blank after baseline correction.
Calibration curve of lornoxicam
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
triethanolamine 5% v/v and diluted to 100 ml with phosphate buffer 
solution pH 6.8 to prepare 100 µg/ml stock solution. The prepared 
stock solution was further diluted to get standard solutions of 5, 7.5, 10, 
12.5, 15, and 17.5 µg/ml, and the absorbance was measured at λ max at 
376 nm, against phosphate buffer solution pH 6.8 as blank. The standard 
graph was plotted by taking a concentration of drug on X-axis and 
absorbance on Y-axis in the concentration range of 5–17.5 µg/ml.
Calculation of dose
The dose of lornoxicam is 4 mg. Therefore, the amount of lornoxicam in 
a film of 4 cm2 is 4 mg. Area of the Petri dish of 9 cm diameter is 63.64 
cm2 so that the amount of drug present to be added to the 63.64cm2 
area of Petri dish is 64 mg.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i9.27098
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Preparation of HPMC E5 mouth dissolving film
Five formulas were prepared using HPMC E5 by casting method as 
shown in Table 1. The specified amount HPMC polymer was weighed 
and dissolved in sufficient quantity of water. The solution was kept 
aside for overnight for swelling of polymer. Further required quantities 
of aspartame and mannitol (as sweetening agents since lornoxicam 
has bitter taste) were dissolved in 2 ml of hot water and added to the 
polymer solution under continuous stirring using magnetic stirrer. 
Isopropyl alcohol was used as a solvent for the drug; polyethylene glycol 
(PEG) 400 was added to the solution as plasticizer at a concentration 
20% of dry polymer. The resulting bubble-free solution was poured 
onto Petri dish and kept in oven at 40°C for 24 h for drying [8].
Preparation of PVA film
Films were prepared using polyvinyl alcohol by casting method as 
shown in Table 2. The specified amount PVA was dissolved in sufficient 
quantity of water at 80°C at hot plate. Glycerin was added to the polymer 
solution as a plasticizer at concentration 20% of dry polymer, and the 
solution was sonicated for 15 min. Poloxamer 407 (act as a surfactant) 
was added to the polymeric solution with sonication. Further required 
aspartame and mannitol were added to the hot polymeric solution as 
sweetening agents. 64 mg of lornoxicam was dispersed in the polymer 
solution and sonicated for 30 min. Finally, vanilla was added as flavoring 
agent to the solution with sonication for 5 min. The resulting bubble-
free solution was poured onto Petri dish and kept in an oven at 40°C for 
24 h for drying. The film was removed from the mold and preserved in 
a aluminum paper and in a desiccator.
Evaluation of lornoxicam film using PVA as a film-forming agent
Appearance of films
Appearance of strip was evaluated by visual observation such as 
transparent and semitransparent nature of strip [9].
Weight variation
10 films were randomly selected from each formulation, and the 
average weight variations were determined. The weight of each film 
was taken using digital weighing balance. The standard deviation (SD) 
of weight was computed from the mean value [10].
Thickness of films
The thickness of the film was measured by micrometer screw gauge 
(digital Vernier caliper) at five different places, at the corners, and at the 
center, and an average of three values and the SD were calculated. This 
is essential to ascertain uniformity in the thickness of the film which is 
directly related to the accuracy of dose in the film [11].
Folding endurance
The folding endurance was determined by repeatedly folding one film 
at the same place until it brokes. The number of times the film folded at 
the same place without breaking or cracking gives the value of folding 
endurance and folded up to 300 times that is satisfactory to reveal good 
film properties [12].
Surface pH
The film to be tested was placed in a Petri dish and was moistened 
with 0.5 ml of distilled water and kept for 30 s. The pH was noted after 
bringing the electrode of the pH meter in contact with the surface of 
the formulation and allowing equilibration for 1 min. The average of 
three determinations for each formulation was taken and the SD was 
calculated [13].
In vitro disintegration test
Disintegration test was performed by placing the film of size 2×2 
cm2 in the glass Petri dish containing 10 ml of water. It was stirred at 
every 10s time interval. The time required for the film to disintegrate 
was recorded, and the results are expressed as the mean of three 
determinations ± SD [14].
Content uniformity
Drug content of lornoxicam films was determined by UV-
spectrophotometric method. For this, one strip of 4 cm2 was dissolved 
in 100 ml of pH 6.8 buffer, then the solution was suitably diluted, and 
the absorbance was recorded at 376 nm [15].
In vitro dissolution studies
In vitro dissolution of fast dissolving film was studied in USP paddle 
dissolution test apparatus using phosphate buffer pH 6.8 as the 
dissolution medium. The temperature was maintained at 37±0.5°C 
throughout the experiment. 5 ml sample was withdrawn at 1, 2, 3, 
4, 5, 10, 15, 20, and 30 min intervals, and the same quantity was 
replaced with phosphate buffer of pH 6.8. The percentage of drug Fig. 1: Chemical structure of lornoxicam
Table 1: Formulation of lornoxicam films using HPMC E5
Formula Lornoxicam (mg) HPMC (mg) PEG 400 (ml) Aspartame (mg) Mannitol (mg) Water (ml) Isopropyl alcohol (ml)
F1 64 750 0.15 100 100 q.s 20
F2 64 1000 0.2 100 100 q.s 20
F3 64 1250 0.25 100 100 q.s 20
F4 64 1500 0.3 100 100 q.s 20
F5 64 2000 0.4 100 100 q.s 20
HPMC: Hydroxypropyl methylcellulose, PEG: Polyethylene glycol
Table 2: Formulation of lornoxicam films using PVA
















F1 64 400 80 120 45 45 q.s q.s
F2 64 500 100 120 45 45 q.s q.s
F3 64 600 120 120 45 45 q.s q.s
F4 64 700 140 120 45 45 q.s q.s
PVA: Polyvinyl alcohol
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released was determined using UV visible spectrophotometer at 
376 nm [16,17].
Fourier-transformed infrared (FTIR) spectroscopic analysis
FTIR spectra of pure lornoxicam, PVA, and the physical mixture of 
lornoxicam and PVA at ratio (1:1) were analyzed using FTIR lambda 
7600-Australia spectroscopy. FTIR spectrum was recorded between 
400 and 4000 cm–1 by KBr disc method.
Differential scanning calorimetry (DSC)
DSC thermograms were recorded using a differential scanning 
calorimeter (DSC-60 plus, Shimadzu). An accurately weighed sample 
(2–4 mg) of pure drug, PVA, and the physical mixture of lornoxicam 
and PVA at ratio (1:1) was heated in hermetically sealed aluminum 
pans under nitrogen purge (100 ml/min) over a temperature range of 
25°C–300°C at a constant rate of 10°C/min [18].
Statistical analysis
ANOVA test (one-way analysis of the variance) and student t-test were 
employed for statistical analysis. When p<0.05, then there would be a 
significant statistical differences [19].
RESULTS AND DISCUSSION
λmax for pure lornoxicam in phosphate buffer solution pH 6.8
100 μg/ml sample was prepared and scanned between 200 and 400 nm. 
The drug showed maximum absorption at 376 nm. Hence, the λmax of 
lornoxicam was found to be 376 nm as shown in Fig. 2.
Calibration curve of lornoxicam
Lornoxicam showed maximum absorption at wavelength 376 nm 
in phosphate buffer (pH 6.8) as shown in Fig. 2. Standard curve was 
plotted by taking absorbance of diluted stock solutions at wavelength 
376 nm. A linear relationship was obtained in Beer–Lambert’s plot of 
lornoxicam which is shown in Fig. 3.
Effect of the type of polymer as film-forming agent
HPMC is a film-forming polymer, having excellent film-forming ability, 
but it had not give a satisfactory results to give a good film since the drug 
is water insoluble and isopropyl alcohol was not efficient to solubilize 
the drug and the dispersion of the drug was not achieved throughout 
the film, while the use of PVA gave a good film that can peel from the 
Petri dish and the drug was dispersed homogeneously throughout the 
film, so PVA was used as selected film-forming polymer.
Effect of plasticizer type
Plasticizers were used to maintain the flexibility of the films, and PEG 
400 was used as plasticizer in the preparation of fast dissolving film, 
but it noticed that it had bitter taste affecting on the palatability of the 
film. Glycerin was found to be better when compared to PEG 400 since 
it acts as plasticizer and sweetening agent.
To improve the palatability of the mouth dissolving films, the natural 
sweeteners and artificial sweeteners are used in combination. 
Lornoxicam is being bitter in taste, and taste masking was achieved by 
the use of sweeteners (mannitol and aspartame) and flavors such as 
vanilla. Mannitol was used as natural sweetener; it was expected to give 
good mouthfeel and cooling sensation when incorporated with other 
sweeteners.
Appearance of lornoxicam film using PVA as a film-forming agent
The prepared films were found to be good without any major film 
manufacturing defects; the film was semitransparent with yellow color 
since the drug has yellow to dark-yellow color as shown in Fig. 4. The 
surface of the film was found to be smooth; there is no sign of picking, 
and cracking except F1 containing 30% of PVA was sticky and excluded 
from the evaluation. The other prepared films F2, F3, and F4 were 
evaluated for post-evaluation parameters.
Weight variations
Ten films each of 4 cm2 were cut from the casted film, and weight 
variation was determined. Weight variation varies from 80.46±2 to 
91.44±3 mg. The result of weight variation is shown in Table 3.
Thickness
As all the formulations contain different amount of polymers, the 
thickness was gradually increased with the amount of polymers. The 
thicknesses of formulated films were found to be in range of 0.071–
0.114 mm. The results are given in Table 3 which shows a gradual 
increase in the thickness.
Folding endurance
Brittleness of the film was determined through the folding endurance. 
It measures the ability of the film to withstand rupture. Any formulated 
Fig. 2: Ultraviolet scan of lornoxicam in phosphate buffer solution 
pH 6.8
Fig. 3: Calibration curve of lornoxicam in phosphate buffer 
solution pH 6.8
Fig.4: Fast dissolving film of lornoxicam
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film has a folding endurance value; a value more than 300 indicates 
acceptable results [19]. Glycerin acts as a plasticizer because it is 
capable to decrease the glass transition temperature. Lowering the 
glass transition temperature increases chain mobility and this, in turns, 
increases in folding endurance [1]. The folding endurance of all the 
formulations was >300, and the results are given in Table 3.
pH surface evaluation
Test the pH of the surface of oral film needs to be done to investigate 
the risk of side effects. Acidic or basic pH may cause disturbance in 
the oral mucosa and impact the rate of hydration of the polymers, so 
it is important to maintain the pH remains close to neutral pH. From 
Table 3, it can be seen that the film has a near neutral pH which is in the 
range of 6.57–6.76. Hence, the dosage has a very small probability to 
irritate the oral mucosa [20].
In vitro disintegration time
It was observed that in vitro disintegration time varies from 30.3±3 to 
52±3.6 s for the three formulations as demonstrated in Table 3 and Fig. 5. 
In vitro disintegration time of lornoxicam film containing PVA as polymer 
was affected by the thickness of the film, and as the amount of polymer 
increases [21], the disintegration time was increased significantly (p<0.05) 
by increasing the concentration of the polymer as in F3 and F4 that contain 
50%w/w and 55% w/w of PVA, respectively, while the disintegration time 
for F2 (40% of PVA) was the lowest. This can be explained as the higher 
concentration of the polymer, the thicker gel will produce on contact with 
the media, which require a longer time to disintegrate [19].
Content uniformity evaluation
Content uniformity test performed to ensure that all films contain a 
uniform weight of drug as desired. Content uniformity is determined by 
estimating the active ingredient contained in each film. Limit of content 
uniformity is 85–115% with a SD which must be ≤6% [22]. From 
Table 3, it can be seen that the levels of drug in the film range between 
95% and 112%. It showed that levels of drug in oral film fulfill the limit 
of content uniformity.
In vitro dissolution study
The in vitro drug release from film of the three formulations was 
performed in triplicate using USP apparatus II (paddle method). 
Dissolution study was performed in pH 6.8 phosphate buffer; the 
release profile was demonstrated in Fig. 6 and and Table 4 shows the 
percentage of drug being dissolved in 30 min. In case of F2 that contains 
40% of PVA formulation, about 87% of drug was released in 5 min 
and was considered as the best formulation. While in case of F3 and 
F4, containing 50% and 55% w/w of PVA, respectively, formulations 
about 40% and 50% of drug released, respectively, in 5 min. This drug 
release pattern indicates that the increased concentration of polymer 
decreases the drug release.
FTIR study
The FTIR spectrum of lornoxicam (Fig. 7) has a characteristic peak at 
3066 cm-1 corresponding to –CH starching of heteroaromatic ring, and 
sharp peak obtained at 1646 cm-1 represents the stretching vibration of 
C=O in structure of primary amide. Other peaks were observed at 1595 
and 1549 cm-1 and were assigned to bending vibrations of the N–H 
group in the secondary amide. The stretching vibrations of the O=S=O 
and C-S groups appeared at 1326 cm-1 and 1425.46 cm-1, respectively. 
Other prominent peaks was appeared at 869.74 cm-1 corresponding 
to –CH aromatic ring bending and heteroaromatics and at 790.67 cm-1 
due to the C–Cl bending vibration. C-N stretching was observed at 
1084.51 cm-1. The presence of all these groups shows similarity with 
actual drug structure which indicates the purity of drug substance [23].
The most characteristic band of PVA (Fig. 8) and its respective 
assignments is observed at 3423 cm-1 and is ascribed to the O–H 
stretching from the intermolecular and intramolecular hydrogen bonds. 
The characteristic peaks of lornoxicam were still present in the physical 
mixture of drug and PVA (Fig. 9) at a ratio of 1:1, indicating no chemical 
interaction between the drug and polymer.
Table 3: Evaluation of physicomechanical parameters of fast dissolving film of lornoxicam
Formula Weight variation (mg) Thickness (mm) Folding endurance pH Disintegration time (s) Drug content (%)
F2 82.9±1 0.081±0.02 >300 6.76±0.12 30.3±3 95±1
F3 80.46±2 0.071±0.013 >300 6.7±0.1 41±3 112±0.43
F4 85.1±3 0.114±0.016 >300 6.57±0.21 52±3.6 96±0.1
The values represent mean ± standard deviation, n=3
Table 4: In vitro dissolution studies of lornoxicam from F2 to F4
Time (min) F2 F3 F4
0 0 0 0
1 7.16±0.08 11,8±0.7 9±0.03
2 25±0.09 13.5±0.3 9±0.06
3 51.5±0.02 20.3±0.06 22±0.4
4 77±0.04 29±0.07 36±0.1
5 87±0.1 40±0.5 50±0.03
10 95±0.045 66±0.021 76±0.05
15 98±0.2 77.5±0.05 82±0.06
20 99±0.3 80±0.04 87±0.063
30 100±0.4 87±0.2 93±0.09
All values expressed as mean ± SD (n=3), F: Formula, SD: Standard deviation
Fig. 5: Disintegration time of lornoxicam film
Fig. 6: Dissolution profile of lornoxicam film F2, F3, and F4. All 
values expressed as mean ± standard deviation (n=3), F = formula 
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Fig. 7: Fourier transformed infrared spectrum of lornoxicam
Fig. 8: Fourier transformed infrared spectrum of polyvinyl alcohol
Fig. 9: Fourier transformed infrared of physical mixture of lornoxicam and polyvinyl alcohol at ratio (1:1)
DSC
DSC curves of lornoxicam, PVA, and physical mixture of lornoxicam and 
PVA at ratio (1:1) were obtained and shown in Figs. 10-12, respectively. 
Pure lornoxicam showed a sharp exothermic peak at 220°C which 
corresponds with the range of melting point of lornoxicam (220–
230°C), and the sharp intense exothermic peak indicates the crystalline 
nature of drug [24,25].
The DSC curve of physical mixture showed a sharp endothermic 
peak at 224°C corresponding to melting point of lornoxicam and the 
exothermic peak of PVA at 191°C indicating that there is no interaction 
between lornoxicam and PVA.
CONCLUSION
In the present research work, an attempt has been made to prepare 
mouth dissolving films of lornoxicam which is NSAID, water-insoluble 
with bitter taste. The fast dissolving films of lornoxicam were prepared 
by solvent casting method using film-forming polymer PVA and glycerol 
as plasticizer. Based on the in vitro disintegration time and dissolution 
profile, formulation F2 was found to be promising and showed a 
disintegration time of 30 s and 87% of drug released in 5 min.
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Fig. 10: Differential scanning calorimetry of lornoxicam
Fig. 11: Differential scanning calorimetry of polyvinyl alcohol
Fig. 12: Differential scanning calorimetry of physical mixture lornoxicam and polyvinyl alcohol
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